About CaReMe
CaReMe is a patient-centric initiative to enable early diagnosis and interdisciplinary, integrated care of people living in the Cardio-Renal-Metabolic (CaReMe) risk continuum. Why? Because an interdisciplinary, integrated approach to CaReMe treatment has been shown to improve clinical outcomes, increase cost effectiveness and enhance both resource utilisation and patients’ overall treatment experience.
Our platform comprises six building blocks; all geared towards providing healthcare professionals with a wealth of practical tools and information, research and data, as well as experience and expert guidance. These resources are designed to promote and facilitate the adoption of an interdisciplinary, integrated and holistic approach to CaReMe treatment. Starting today.
“Treating CaReMe conditions individually isn’t just a headache for the doctor trying to coordinate all the patient’s care; it is also a headache for the patient, who has to spend so much time seeing so many different doctors. That’s why we need to treat CaReMe patients at integrated Clinics.” – Prof Jonas Spaak
Did you know?
MILLION people worldwide die from cardiovascular disease annually1
MILLION people worldwide have chronic kidney disease2
MILLION adults worldwide have diabetes3
% of chronic kidney disease patients have type-2 diabetes4
% of type-2 diabetes-associated deaths are due to cardiovascular diseases5
% of people with diabetes have at least two comorbid conditions6
But why?
So, what are you waiting for?
CaReMe diseases are the leading causes of morbidity and mortality around the world, with each CaReMe condition increasing the risk of a patient developing yet another CaReMe condition. It’s a vicious cycle that cannot be stopped by addressing only one part of the problem.
According to research, more than 50% of type-2 diabetes-associated deaths are a result of cardiovascular disease. Around 40% of chronic kidney disease patients have type-2 diabetes, while a 2016 study published in Current Medical Research and Opinion showed that nearly 90% of people with diabetes have at least two underlying disorders.
Treating individual CaReMe conditions can lead to delayed diagnosis of other CaReMe conditions, which can lead to an increased risk of progression – not to mention an extremely frustrated patient who is left feeling disempowered as they shuffle from one specialist to the next.
Integrating the treatment of CaReMe conditions can avoid many of these (and many other) complications, enabling healthcare professionals to manage their patients – and patients to manage their conditions – more effectively than ever.
Data from the Haverty Cardiometabolic Center of Excellence, in the US, has shown that patients who receive integrated CaReMe treatment experience a significantly greater reduction in cardiovascular disease risk factors such as LDL cholesterol, systolic blood pressure, HbAc1 and weight. The use of guideline-directed medical therapies was also 20-fold higher in the group that received CaReMe treatment at this centre.
And it isn’t just a patient’s clinical outcomes that improve. Data from an integrated clinic in St Paul’s Hospital, Vancouver, has shown that CaReMe comorbidities incur significantly lower costs when treated in an interdisciplinary, integrated clinic – with a potential saving of $1 278 per patient every year.
CaReMe diseases are the leading causes of morbidity and mortality around the world, with each CaReMe condition increasing the risk of a patient developing yet another CaReMe condition. It’s a vicious cycle that cannot be stopped by addressing only one part of the problem.
According to research, more than 50% of type-2 diabetes-associated deaths are a result of cardiovascular disease. Around 40% of chronic kidney disease patients have type-2 diabetes, while a 2016 study published in Current Medical Research and Opinion showed that nearly 90% of people with diabetes have at least two underlying disorders.
Treating individual CaReMe conditions can lead to delayed diagnosis of other CaReMe conditions, which can lead to an increased risk of progression – not to mention an extremely frustrated patient who is left feeling disempowered as they shuffle from one specialist to the next.
Integrating the treatment of CaReMe conditions can avoid many of these (and many other) complications, enabling healthcare professionals to manage their patients – and patients to manage their conditions – more effectively than ever.
Data from the Haverty Cardiometabolic Center of Excellence, in the US, has shown that patients who receive integrated CaReMe treatment experience a significantly greater reduction in cardiovascular disease risk factors such as LDL cholesterol, systolic blood pressure, HbAc1 and weight. The use of guideline-directed medical therapies was also 20-fold higher in the group that received CaReMe treatment at this centre.
And it isn’t just a patient’s clinical outcomes that improve. Data from an integrated clinic in St Paul’s Hospital, Vancouver, has shown that CaReMe comorbidities incur significantly lower costs when treated in an interdisciplinary, integrated clinic – with a potential saving of $1 278 per patient every year.
- World Health Organization. WHO World Heart Day 2017: Scale up prevention of heart attack and stroke: World Health Organization; 2017 [cited 2018 Jul 25].https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
- Hill NR, et al. Global prevalence of chronic kidney disease – A systematic review and meta-analysis. PLoS One [Internet]. 2016;10:1–18. http://dx.doi.org/10.1371/journal.pone.0158765.
- International Diabetes Federation. IDF Diabetes Atlas [Internet]. Ninth Edit. Karuranga S, Malanda B, Saeedi P, Salpea P, editors. 2019. 1–170 p. https://diabetesatlas.org/en/.
- Alicic RZ, et al. Diabetic kidney disease: Challenges, progress, and possibilities. Clin J Am Soc Nephrol [Internet]. 2017;12(18)2032-2045. https://cjasn.asnjournals.org/content/12/12/2032.
- Holman RR, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med [Internet]. 2008 Oct 9;359(15):1577–89. https://doi.org/10.1056/NEJMoa0806470.
- Iglay K, Hannachi H, Joseph Howie P, Xu J, Li X, Engel SS, et al. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin [Internet]. 2016 Jul 2;32(7):1243–52. https://doi.org/10.1185/03007995.2016.1168291.
The bottom line?
So, what are you waiting for?
Copyright by CaReMe Global Alliance 2025. All rights reserved.
Copyright by CaReMe Global Alliance 2025. All rights reserved.